Sequence: SHGRITFAYFAN
| Experiment Id | EXP002491 |
|---|---|
| Paper | Delivery System Targeting Hemagglutinin of Influenza Virus A to Facilitate Antisense-Based Anti-H1N1 |
| Peptide | HA-binding peptide HABP / H17 |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | Not clearly specified for in vitro assay; plaque assay after IAV-infected A549 cells treated with FT-HABP for 12 h |
| Mixing Ratio | |
| Formulation Format | Covalent peptide-ODN conjugate |
| Formulation Components | HABP peptide + anti-IAV flutide ODN via EMCS linker |
| Size Nm | |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | A549 cells infected with influenza A/FM/1/86 (H1N1) |
| Animal Model | |
| Administration Route | |
| Output Type | Antiviral functional effect / plaque assay |
| Output Value | Plaque formation inhibited more strongly by FT-HABP than unconjugated FT; ~75% inhibition reported in abstract; higher inhibitory effect than ODN alone in Figure 4A |
| Output Units | |
| Output Notes | FITC-HABP colocalized with Cy3-IAV in A549 cells; FT-HABP reduced viral replication in vitro. In vitro effect does not qualify as delivery_success_class=1. |
| Toxicity Notes | No specific toxicity issue reported for FT-HABP in the curated assay. |
| Curation Notes |